<DOC>
	<DOCNO>NCT02042378</DOCNO>
	<brief_summary>The purpose study determine whether oral rucaparib effective treatment patient locally advance metastatic pancreatic cancer know deleterious BRCA mutation .</brief_summary>
	<brief_title>A Study Rucaparib Patients With Pancreatic Cancer Known Deleterious BRCA Mutation</brief_title>
	<detailed_description>Rucaparib orally available , small molecule inhibitor poly-adenosine diphosphate [ ADP ] ribose polymerase ( PARP ) inhibit specific DNA repair pathway know base excision repair ( BER ) . PARP inhibitor ( PARPi ) show effectively kill tumor defect BRCA1 BRCA2 . Clinical benefit observe patient gBRCA mutation well somatic BRCA ( sBRCA ) mutation . Clinical data also show pancreatic cancer patient gBRCA mutation benefit PARPi treatment . Clinical activity PARP inhibitor BRCA-mutated pancreatic cancer combine paucity 2nd line therapy support evaluation rucaparib pancreatic cancer patient know harbor deleterious BRCA mutation .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<criteria>Confirmed diagnosis pancreatic cancer ( ductal adenocarcinoma relate subtypes eligible ; endocrine neuroendocrine tumor exclude ) Received least 1 , 2 , chemotherapybased regimen locally advance metastatic disease relapse progressive disease . Patients longer able continue treatment chemotherapy due intolerable toxicity may consider study participation provide radiology assessment confirm either stable disease disease progression ( i.e . response treatment ) Documented deleterious suspect deleterious ( equivalent interpretation ) BRCA mutation ( germline somatic ) assess local laboratory Measurable disease Presence another active cancer Prior treatment PARP inhibitor , include rucaparib . Patients treat prior iniparib eligible . Symptomatic and/or untreated central nervous system metastasis . Clinical evidence malabsorption and/or gastrointestinal disorder defect would , opinion investigator , interfere absorption rucaparib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>BRCA</keyword>
	<keyword>BRCA mutation</keyword>
	<keyword>germline BRCA</keyword>
	<keyword>somatic BRCA</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>rucaparib</keyword>
	<keyword>CO-338</keyword>
	<keyword>PF 01367338</keyword>
	<keyword>AG 14699</keyword>
	<keyword>Clovis</keyword>
	<keyword>Clovis Oncology</keyword>
	<keyword>RucaPanc</keyword>
</DOC>